Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Next Gen Technology Enables Robust, Straightforward and Flexible Molecular Diagnostics in Any Environment

By LabMedica International staff writers
Posted on 24 Mar 2023

The implementation of point-of-care systems is often hindered by challenges related to sample preparation, reagent storage, and user proficiency. More...

Now, a next-generation ‘Anywhere, anytime, by anyone’ molecular detection technology aims to shift the detection and monitoring of viral infections to point-of-care and beyond clinical settings. The technology, which allows for rapid and precise measurement and quantification of viral RNA, DNA, antigens, or antibodies, can be used by anyone, anywhere, at any time.

AltraTech Limited’s (Cork, Ireland) innovative technology integrates nanotechnology, semiconductor technology, and novel PNA chemistry to create a distinct and robust assay. This assay, called Molecular Detection by Proxy, is a bead-based technology that employs ultra-sensitive capacitance detection. The assay involves three critical stages. The first stage uses exclusive bioorthogonal PNAs to overcome the challenge of extracting genetic material from a biological sample without any sample preparation. These synthetic nucleic acids are incredibly specific and can be directly introduced into the sample.

The target is then captured onto a magnetic bead, following which the captured molecules are magnetically removed from the sample and tethered onto coded nanoparticles. These nanoparticles are representative of the biological target, with each particle equivalent to a single target. Finally, the particles are released over a highly sensitive, bioorthogonal CMOS biosensor chip, resulting in a change of capacitance. The higher the number of particles, the greater the measured capacitance, leading to a linear correlation with the initial target present in the sample.

As a result, the assay can be multiplexed with ease and used to measure other targets, including antibodies or antigens, within the same test. Moreover, as soon as a new genome is accessible, the company’s core bioorthogonal PNA chemistry can be promptly programmed with the specific targeting sequences, enabling a new test to be deployed within days. The assay will be integrated into a solid-state device that can be miniaturized, commercialized, and mass-produced.

Related Links:
AltraTech Limited 


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Automated MALDI-TOF MS System
EXS 3000
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.